false 0001626971 0001626971 2024-06-13 2024-06-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 13, 2024

 

 

CORVUS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 
         
Delaware   001-37719   46-4670809

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification Number)

 

863 Mitten Road, Suite 102

Burlingame, CA

 94010
(Address of principal executive offices) (Zip code)

 

Registrant’s telephone number, including area code: (650) 900-4520

 

Former name or former address, if changed since last report: Not applicable

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: 

 

Title of each class Trading symbol(s) Name of each exchange on which registered
Common Stock, Par Value $0.0001 per share CRVS Nasdaq Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐ 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On June 13, 2024, Corvus Pharmaceuticals, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). Only stockholders of record at the close of business on April 18, 2024, the record date for the Annual Meeting, were entitled to vote at the Annual Meeting. As of the record date, there were 49,038,582 shares of the Company’s common stock outstanding and entitled to vote at the Annual Meeting. At the Annual Meeting, 35,968,782 shares of the Company’s common stock were voted in person or by proxy for the three proposals set forth below, each of which is described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 26, 2024.

 

The tabulation of the stockholder votes on each proposal brought before the Annual Meeting is as follows:

 

Proposal No. 1 — Election of Director

The Company’s stockholders elected the Class II director nominee below to the Company’s Board of Directors to hold office until the 2027 Annual Meeting of Stockholders or until his respective successor is elected and qualified or appointed, or the earlier of his death, resignation or removal. 

 

Class II Director Nominee     Votes For   Votes Withheld   Broker Non-Votes
Scott W. Morrison   19,667,286   5,398,946   10,902,550

 

Proposal No. 2 — Ratification of Selection of Independent Registered Accounting Firm

The Company’s stockholders ratified the selection of PricewaterhouseCoopers LLC as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024. 

 

Votes For   Votes Against   Abstain  
35,776,658   65,997   126,127  

 

 

Proposal No. 3 —Non-Binding Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers

On a non-binding advisory basis, the Company’s stockholders approved the compensation of the Company’s named executive officers. 

 

Votes For   Votes Against   Abstain   Broker Non-Votes
24,424,413     413,670   234,233   10,896,466

 

 

 

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  CORVUS PHARMACEUTICALS, INC.  
Date: June 14, 2024      
  By: /s/ Leiv Lea  
    Leiv Lea  
    Chief Financial Officer  

 

 

v3.24.1.1.u2
Cover
Jun. 13, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 13, 2024
Entity File Number 001-37719
Entity Registrant Name CORVUS PHARMACEUTICALS, INC.
Entity Central Index Key 0001626971
Entity Tax Identification Number 46-4670809
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 863 Mitten Road
Entity Address, Address Line Two Suite 102
Entity Address, City or Town Burlingame
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94010
City Area Code (650)
Local Phone Number 900-4520
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, Par Value $0.0001 per share
Trading Symbol CRVS
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Corvus Pharmaceuticals (NASDAQ:CRVS)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024 Click aqui para mais gráficos Corvus Pharmaceuticals.
Corvus Pharmaceuticals (NASDAQ:CRVS)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024 Click aqui para mais gráficos Corvus Pharmaceuticals.